Literature DB >> 15207265

Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients.

Silke Frahm1, Victor-F Mautner, Hilde Brems, Eric Legius, Maria Debiec-Rychter, Reinhard E Friedrich, Wolfram T Knöfel, Matthias Peiper, Lan Kluwe.   

Abstract

Neurofibromatosis type 1 (NF1) patients have an 8-13% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNST) which have a very poor prognosis. In this study, cells from eight MPNSTs (six primary and two recurrences) of six clinically and genetically well-characterized NF1 patients were taken into culture. Tracing of loss of heterozygosity (LOH) of the NF1, p53, and p16 gene regions or of abnormal karyotypes enabled identification of tumor cells from five MPNSTs. In two other MPNST-derived cell cultures, LOH of the relevant regions in the original tumors could not be detected, indicating that the obtained cells were nonneoplastic cells. Cells from most MPNSTs grew only under standard culture conditions but not under conditions optimized for Schwann cells. These cells were S100-negative and did not exhibit spindle shape which is a characteristic of Schwann cells. Drastically increased proliferation rates were found for most of the MPNST cells in comparison to Schwann cells derived from benign neurofibromas. Our study demonstrates that genetic analysis is effective and essential for verification of MPNST tumor cells in culture. These verified MPNST cells are valuable for further investigations of the biology and pathogenesis of this malignancy as well as for in vitro pharmacologic studies essential for the development of new therapies.

Entities:  

Mesh:

Year:  2004        PMID: 15207265     DOI: 10.1016/j.nbd.2004.01.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  33 in total

1.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

2.  Effects of pigment epithelium derived factor (PEDF) on malignant peripheral nerve sheath tumours (MPNSTs).

Authors:  Maria Demestre; Menderes Yusuf Terzi; Victor Mautner; Peter Vajkoczy; Andreas Kurtz; Ana Luisa Piña
Journal:  J Neurooncol       Date:  2013-12       Impact factor: 4.130

3.  The neurofibromin GAP-related domain rescues endothelial but not neural crest development in Nf1 mice.

Authors:  Fraz A Ismat; Junwang Xu; Min Min Lu; Jonathan A Epstein
Journal:  J Clin Invest       Date:  2006-08-10       Impact factor: 14.808

4.  A case of intra-dural malignant peripheral nerve sheath tumor in thoracic spine associated with neurofibromatosis type 1.

Authors:  Baki S Albayrak; Askin Gorgulu; Turgay Kose
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

5.  A retroperitoneal NF1-independent malignant peripheral nerve sheath tumor with elevated serum CA125: case report and discussion.

Authors:  Bing Yan; Xianze Meng; Bian Shi; Jun Shi; Zhifeng Qin; Pinkang Wei
Journal:  J Neurooncol       Date:  2012-04-19       Impact factor: 4.130

6.  Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.

Authors:  Adrienne L Watson; Eric P Rahrmann; Branden S Moriarity; Kwangmin Choi; Caitlin B Conboy; Andrew D Greeley; Amanda L Halfond; Leah K Anderson; Brian R Wahl; Vincent W Keng; Anthony E Rizzardi; Colleen L Forster; Margaret H Collins; Aaron L Sarver; Margaret R Wallace; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Cancer Discov       Date:  2013-03-27       Impact factor: 39.397

7.  EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.

Authors:  J Wu; D M Patmore; E Jousma; D W Eaves; K Breving; A V Patel; E B Schwartz; J R Fuchs; T P Cripe; A O Stemmer-Rachamimov; N Ratner
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

8.  Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.

Authors:  Maria Demestre; Jan Herzberg; Nikola Holtkamp; Christian Hagel; David Reuss; Reinhard E Friedrich; Lan Kluwe; Andreas Von Deimling; Victor-F Mautner; Andreas Kurtz
Journal:  J Neurooncol       Date:  2009-11-17       Impact factor: 4.130

9.  In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1.

Authors:  Deanna M Patmore; Sara Welch; Patricia C Fulkerson; Jianqiang Wu; Kwangmin Choi; David Eaves; Jennifer J Kordich; Margaret H Collins; Timothy P Cripe; Nancy Ratner
Journal:  Cancer Res       Date:  2012-08-23       Impact factor: 12.701

10.  Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis.

Authors:  Chengkai Dai; Sandro Santagata; Zijian Tang; Jiayuan Shi; Junxia Cao; Hyoungtae Kwon; Roderick T Bronson; Luke Whitesell; Susan Lindquist
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.